Study of osivelotor for sickle cell disease
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study tests an investigational medicine called osivelotor for people with sickle cell disease (SCD). The goal is to see if it can reduce pain crises and improve overall health. It is for adults and adolescents aged 12 and older.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have sickle cell disease with the HbSS or HbSβ-zero type.
- Your hemoglobin level must be between 5.5 and 10.5 g/dL at screening.
- If you take hydroxyurea or L-glutamine, your dose must have been unchanged for at least 90 days before the study starts.
- You must have had 2 to 10 pain crises (called vaso-occlusive crises) in the past 12 months.
- You cannot have had a blood transfusion in the last 90 days, and you cannot be pregnant or breastfeeding.
- You cannot have been hospitalized for a sickle cell crisis in the last 14 days.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill called etavopivat for people with sickle cell disease who have had some pain crises in the past year. The goal is to see if it reduces these crisis episodes.
This trial tests an investigational drug called DISC-3405 in people with sickle cell disease (SCD) to see if it is safe and how it affects your body. It may be an option if you have certain SCD complications or lab results.
This trial tests whether giving high-flow oxygen can help treat a painful sickle cell “vaso-occlusive crisis” (VOC) and lower the risk of a serious lung complication. You may be eligible if you’re an adult with sickle cell disease experiencing an opioid-requiring pain flare and have higher risk for lung trouble.
This trial tests a new drug, etavopivat, to see how it works in children with sickle cell disease. It may help reduce painful crises and other complications.
This trial tests a new medicine called ITU512 in two groups: healthy volunteers and people with sickle cell disease. In the second part, researchers want to see if ITU512 can help manage sickle cell disease.
This trial studies etavopivat to see if it can improve blood-flow measurements in the brain that predict future stroke risk in children with sickle cell disease. If you qualify, you would take the study medicine and be monitored with brain blood-flow testing.
Hear when a new Sickle Cell Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.